Navigation Links
World Health Day is April 7 with a Focus on Antibiotic Resistance
Date:4/4/2011

SAN DIEGO, April 4, 2011 /PRNewswire/ -- Antibiotics are among the most important advances in human health, but their use and misuse over the past 70 years have increased the number and types of microorganisms resistant to antibiotics – resulting in deaths, greater suffering and disability, and higher healthcare costs. For World Health Day 2011, the World Health Organization will call on governments and stakeholders to implement the policies and practices needed to prevent and counter the emergence of highly resistant microorganisms. The challenge posed to the pharmaceutical and biotechnology industries is loud and clear – only seven new antibiotics have been introduced since 2003. A press conference on April 7 will feature innovators in antibiotic research and development from industry and academia that are making strides to combat this problem.

WHAT:

Press Conference: Innovation in Antibiotics; Medicine for the Next Wave of Bacterial Infections

WHO:

Jeffrey Stein, Ph.D., President and CEO, Trius Therapeutics

Trius is focusing on the development of innovative antibiotics for life-threatening infections. Trius is in the final stage of clinical development for torezolid phosphate, a next generation antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including those caused by methicillin-resistant Staphylococcus aureus (MRSA).Trius has worked closely with FDA to define a path to market approval for antibiotics that are fast acting and with low acquisition of microbial resistance.

Daniel Burgess, President and CEO, Mpex Pharmaceuticals

Mpex is in the final stage of clinical testing of a proprietary inhalable formulation of levofloxacin for the treatment of microbial infections in patients with cystic fibrosis. The company's mission is to develop important new therapies to combat the growing issue of antibiotic resistance.

Andrei Osterman, Ph.D., Associate Professor Bioinformatics and Systems Biology, Sanford-Burnham Medical Research Institute

Dr. Osterman's research focuses on discovering the molecular mechanisms of disease, the true starting point for understanding what contributes to bacterial resistance. Bacteria are devilishly smart and have adapted to the weapons the pharmaceutical industry has created to fight them. Dr. Osterman and his colleagues are looking for the molecular weaknesses that we can exploit to attack resistant bacteria, with an eye towards translating lab discoveries into treatments.

Joe Panetta, President and CEO, BIOCOM

BIOCOM is the largest regional life science association in the world and represents more than 550 member companies in Southern California.

WHEN: Thursday, April 7, 2011 at 2:00 p.m. – 3:00 p.m. Pacific Time

WHERE: Sanford Children's Health Research Center, Sanford-Burnham Medical Research Institute, 10905 Road to the Cure, San Diego, CA 92121 or via webcast http://investor.triusrx.com/events.cfm.

RSVP:
Carolyn Hawley
Canale Communications
619-849-5375
carolyn@canalecomm.com

Organized by Canale Communications


'/>"/>
SOURCE Canale Communications
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... 24, 2017 IBM (NYSE: IBM ) has ... for Solid-State Arrays (SSA) for the fourth year in a ... to Gartner, "Vendors in the Leaders quadrant have the highest ... A vendor in the Leaders quadrant has the market share, ... acceptance of new technologies. These vendors demonstrate a clear understanding ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 ... spending on brand medicines, generics and the supply chain account for ... just half of this (7 percent)? Or that the ... venture capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... ... provider in the United States, today announced its partnership with financial technology company, ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Engineers at the ... because it produces the same kind of electrical energy that the body uses. ... of moving electrons. This flow of electrons out of the battery is generated by ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to ... Department of Health Care Services, will facilitate the development of a hub and ...
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
(Date:7/24/2017)... Solana Beach, California (PRWEB) , ... July 24, ... ... and commercialization of autologous fat (adipose) transfer systems announces the issuance of United ... (the ‘324 patent) for its adipose filtration technology. The '398 and '324 ...
Breaking Medicine News(10 mins):